PTAB challenges

The provided "PTAB proceedings on file" list serves as the canonical ground truth for this analysis. It contains one proceeding, IPR2025-01107. There are discrepancies between the previously generated "Litigation summary" and the "PTAB proceedings on file" for IPR2025-01107. For the purpose of this task, the "PTAB proceedings on file" information will be prioritized as instructed.

Specifically, the "Previously generated sections" stated:

• Filing Date: August 12, 2024
• Petitioner: Unified Patents
• Outcome/Current Status: Not Instituted - Procedural

The "PTAB proceedings on file" states:

• Filed: 2025-06-06
• Petitioner: MSN Pharmaceuticals, Inc. et al.
• Status: Discretionary Denial

These discrepancies are noted, and the analysis below will proceed with the data from "PTAB proceedings on file."

Proceedings overview

There is one AIA trial proceeding on file for US patent 11013729. This proceeding resulted in a discretionary denial of institution, meaning no claims were invalidated or sustained by the PTAB. This outcome gives a defendant a stronger defensive posture against future IPRs based on similar grounds, as the PTAB has already exercised its discretion not to institute.

IPR2025-01107 — MSN Pharmaceuticals, Inc. et al. v. Pratibha S. Pilgaonkar et al. (Patent Owner not explicitly named in PTAB proceedings on file, but Breckenridge Pharmaceutical Inc. is the current assignee)

• Type: Inter Partes Review
• Filed: 2025-06-06 [cite: The "PTAB proceedings on file" section of the prompt states "IPR2025-01107 — IPR — filed 2025-06-06".]
• Status: Discretionary Denial. This means the PTAB declined to institute the IPR based on discretionary factors, rather than on the merits of patentability. [cite: The "PTAB proceedings on file" section of the prompt states "status: Discretionary Denial".]
• Judge panel: Information not publicly available through direct search results at this time.
• Petition grounds: Information regarding specific claims challenged, prior art, and statutory bases (§ 102 / § 103 / § 112) is not available from the provided prompt or easily discoverable via general web search for a denied IPR without access to the full petition and decision.
• Institution decision: Denied. The institution decision was a discretionary denial, issued on an unspecified date (last modified 2025-11-18). The specific reasoning for the discretionary denial would be detailed in the PTAB's decision but is not publicly available through general web search without access to the official PTAB records for this specific case. [cite: The "PTAB proceedings on file" section of the prompt states "status: Discretionary Denial" and "last modified 2025-11-18".]
• Final Written Decision: Not applicable, as institution was denied.
• Settlement / termination: Not applicable, as institution was denied.
• Appeal: Not applicable, as institution was denied.
• Defensive value: The discretionary denial of this IPR suggests that the PTAB found reasons, beyond the merits of the prior art arguments, to decline review of the patent. This could imply a harder path for future petitioners seeking to challenge the patent on similar grounds, particularly if the discretionary denial was based on factors such as parallel district court litigation or a lack of efficient use of PTAB resources. An IPR-based defense for future challengers will be more challenging if they rely on grounds similar to those raised in this denied petition.

Strategic summary

Currently, all claims of US patent 11013729 remain SUSTAINED or UNTESTED at the PTAB, as the single IPR filed (IPR2025-01107) resulted in a discretionary denial of institution. No claims have been canceled through PTAB proceedings. This means the patent has not been narrowed by AIA trials, and its claims retain their full scope as granted.

The estoppel landscape under § 315(e)(2) for this particular proceeding is likely narrow. Since institution was denied on discretionary grounds rather than a decision on the merits, it is less clear what specific prior-art grounds, if any, future petitioners (or their privies) would be barred from raising. Generally, estoppel applies to grounds actually raised and decided or that reasonably could have been raised. Without a decision on the merits, the estoppel effect might be limited, but the precedent of a discretionary denial could influence future petitions. For a defendant currently being asserted against, this means many prior-art grounds might still be theoretically available for a new IPR, though the PTAB's earlier discretionary decision would need to be carefully considered.

The pattern signals indicate that a defensive aggregator, Unified Patents, was involved in the parallel IPR information from the Google Patents legal status, though the canonical PTAB proceedings list indicates MSN Pharmaceuticals, Inc. as the petitioner. The current status of discretionary denial suggests the patent owner (Breckenridge Pharmaceutical Inc. as the current assignee) successfully argued against institution, potentially based on factors unrelated to the patent's validity in the face of the cited prior art. This indicates the patent owner is actively defending the patent at the PTAB.

Recommended next steps

• Since IPR2025-01107 resulted in a discretionary denial, there is no Final Written Decision to link to that invalidates claims. All claims of US11013729 remain active.
• For any entity considering challenging this patent via IPR, it is crucial to analyze the PTAB's institution decision for IPR2025-01107. Understanding the specific reasons for the discretionary denial will be paramount to crafting a successful future petition. Accessing the full PTAB record for IPR2025-01107 through the USPTO PTAB E2E system is highly recommended to review the petition, patent owner preliminary response, and the Board's decision.
• If assertion is being made against this patent, the current lack of invalidated claims means any infringement theory can proceed without immediate PTAB-induced narrowing. However, the existing litigation in Delaware District Court (1:24-cv-00571) indicates ongoing challenges, which might provide further insights into claim interpretation or validity arguments being used by the patent owner or challenger.